Lack of cross-hepatotoxicity between voriconazole and posaconazole [5]

Clinical Infectious Diseases

Volumn 45, Issue 6, 2007, Pages 803-805

  Foo, Hong ^a   Gottlieb, Thomas ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FLUCONAZOLE; MEROPENEM; POSACONAZOLE; STEROID; VANCOMYCIN; VORICONAZOLE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; COCCIDIOIDOMYCOSIS; CROSS REACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FUNGAL MENINGITIS; FUNGUS IDENTIFICATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERIATRIC PATIENT; HUMAN; HYPOGAMMAGLOBULINEMIA; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; VITRECTOMY;

AGED; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; HUMANS; LIVER DISEASES; PYRIMIDINES; TRIAZOLES;

EID: 34548479250     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521173     Document Type: Letter

References (7)

1. Spellberg B, Rieg G, Bayer A, et al. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis 2003; 36:1091-3.
2. Smith J, Safdar V, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-72.
3. Lau A, Chen S, Sorrell T, et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 2007; 45:380-5.
4. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67:269-98.
5. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropaenia and persistent fever. N Engl J Med 2002; 346:225-34.
6. Vfend (voriconazole) [package insert]. Sydney Australia: Pfizer Australia, 2006.
7. Lutsar I, Hodges MR, Tomaszewski K, et al. Safety of voriconazole and dose individualization. Clin Infect Dis 2003; 36:1087-8.